Imeik Technology Development Co., Ltd.

Imeik Technology Development Co., Ltd. is China's dominant domestic manufacturer of injectable aesthetic products, long celebrated by capital markets as the "Moutai of Medical Aesthetics" for its extraordinary gross margins exceeding 90%. Headquartered in Beijing, China, the company reported 2025 full-year revenue of approximately ¥2.453 billion, representing an 18.94% decline year-over-year, while net profit attributable to shareholders reached ¥1.291 billion — a 34.05% decrease marking Imeik's first simultaneous top-and-bottom-line contraction since its 2016 listing. Despite the cyclical downturn driven by China's consumer spending slowdown and intensifying domestic competition, Imeik's manufacturing output remained formidable: its Beijing production base delivered 5.12 million solution-type injection syringes (led by the flagship Hearty/Hearty series for neck wrinkle correction) and 696,400 gel-type injection products (including the premium PLLA-based Rebom Angel line).

Imeik's competitive advantage is built upon its proprietary R&D pipeline and self-operated manufacturing infrastructure that has systematically addressed underserved clinical niches in the Chinese market. The company's Hearty franchise — the world's first injectable product specifically indicated for neck wrinkle correction — established a dominant market position with minimal direct competition for nearly a decade. The Rebom Angel (PLLA-based biostimulator) and Bonita (long-lasting PVA-based filler) represent premium-tier products that command significantly higher average selling prices than conventional HA fillers. Imeik's sterile manufacturing facilities in Beijing operate under China's NMPA regulatory framework, producing injectable solutions and gels at industrial scale while maintaining pharmaceutical-grade quality control.

In response to 2025's revenue headwinds, Imeik executed an aggressive strategic pivot. The most transformative milestone was securing the exclusive Chinese distribution and drug registration rights for South Korea's Huons BioPharma injectable botulinum toxin type A product, completing the critical "HA filler + neurotoxin" golden pipeline that has defined every global aesthetics leader. Simultaneously, Imeik advanced its internationalization strategy by forming a joint fund to acquire a controlling stake in South Korea's Regen Biotech — a manufacturer of PLA-based fillers and collagen products — marking Imeik's first major overseas manufacturing investment. These moves signal a deliberate transition from a China-centric injectables company to a globally integrated aesthetics manufacturer.

Strengths:
• Dominant domestic manufacturing position — China's leading injectable aesthetics manufacturer with 5.12M syringes + 696K gel products in 2025
• Extraordinary gross margins (>90%) — reflecting pricing power of differentiated, regulatorily protected products manufactured in-house
• First-mover advantage — Hearty franchise enjoyed nearly a decade with minimal competition in neck wrinkle correction
• Pipeline completion strategy — securing Huons toxin distribution completes the "HA filler + neurotoxin" golden pipeline
• International expansion via M&A — acquisition of controlling stake in Korea's Regen Biotech provides overseas manufacturing assets

Weaknesses:
• Revenue contraction — 18.94% decline in 2025 reflects vulnerability to China's consumer spending slowdown
• Single-market concentration — predominant dependence on China's domestic market limits diversification
• No proprietary neurotoxin manufacturing — relies on distribution partnership rather than owning toxin production, creating long-term margin vulnerability